Bank Of America Corp Annovis Bio, Inc. Transaction History

Bank Of America Corp

$1.21 Trillion
Q1 2025

A detailed history of Bank Of America Corp transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 136 shares of ANVS stock, worth $201. This represents 0.0% of its overall portfolio holdings.

Number of Shares

136

Previous 84 61.9%

Holding current value

$201

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.5 - $5.39 $78 - $280	52 Added 61.9%	136 $0
Q4 2024 Feb 14, 2025	SELL	$4.37 - $9.87 $26,202 - $59,180	-5,996 Reduced 98.62%	84 $0
Q3 2024 Nov 14, 2024	BUY	$5.27 - $15.46 $5,349 - $15,691	1,015 Added 20.04%	6,080 $49,000
Q2 2024 Aug 14, 2024	SELL	$4.82 - $18.01 $2,164 - $8,086	-449 Reduced 8.14%	5,065 $29,000
Q1 2024 May 15, 2024	BUY	$8.47 - $18.93 $19,015 - $42,497	2,245 Added 68.68%	5,514 $65,000
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $17,160 - $60,665	3,092 Added 1746.89%	3,269 $61,000
Q2 2023 Aug 14, 2023	BUY	$11.95 - $16.31 $2,115 - $2,886	177 New	177 $2,000
Q4 2022 Feb 10, 2023	SELL	$10.99 - $13.8 $10,077 - $12,654	-917 Reduced 46.06%	1,074 $14,000
Q3 2022 Nov 14, 2022	SELL	$10.26 - $21.81 $68,444 - $145,494	-6,671 Reduced 77.01%	1,991 $27,000
Q2 2022 Aug 12, 2022	BUY	$8.61 - $13.87 $12,863 - $20,721	1,494 Added 20.84%	8,662 $98,000
Q1 2022 May 16, 2022	SELL	$11.84 - $19.78 $58,998 - $98,563	-4,983 Reduced 41.01%	7,168 $96,000
Q4 2021 Feb 08, 2022	SELL	$17.58 - $37.67 $93,648 - $200,668	-5,327 Reduced 30.48%	12,151 $214,000
Q3 2021 Nov 15, 2021	BUY	$30.95 - $120.97 $540,944 - $2.11 Million	17,478 New	17,478 $555,000

Others Institutions Holding ANVS

# of Institutions

Shares Held

2.06M

Call Options Held

54.5K

Put Options Held

422K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $12.1M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Annovis Bio, Inc. Transaction History